Ronald de Wit

机构：Erasmus MC, Erasmus MC Cancer Institute · ORCID：0000-0002-1954-090X

发表论文 624 篇 · 总被引 43036 次 · h-index 88

代表论文

Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial (2024 · The Lancet Oncology · 被引 95)
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study (2024 · Prostate Cancer and Prostatic Diseases · 被引 16)
Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study (2024 · BMC Cancer · 被引 15)
Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. (2025 · Journal of Clinical Oncology · 被引 9)
Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer—A Patient Cohort Analysis (2025 · European Urology Oncology · 被引 3)
Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum‐containing chemotherapy: Post hoc analysis of KEYNOTE‐052 and LEAP‐011 (2024 · Cancer · 被引 2)